July 26, 2017 at 7:30 PM EDT WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Sienna. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 650,000 shares of common stock at the initial public offering price, less the underwriting discount. Sienna’s common stock has been approved for listing on The NASDAQ Global Select Market and is expected to begin

July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments. All existing investors participated in the round including U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures and Osage University Partners. In conjunction with the financing, eFFECTOR has appointed Elain